Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $295,835.

  • Axsome Therapeutics' Gains from Sales and Divestitures rose 19.48% to $295,835 in Q3 2025 from the same period last year, while for Sep 2025 it was $295,835, marking a year-over-year increase of 19.48%. This contributed to the annual value of $267,779 for FY2024, which is 37.73% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Gains from Sales and Divestitures of $295,835 as of Q3 2025, which was up 10.22% from $268,394 recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Gains from Sales and Divestitures peaked at $295,835 during Q3 2025, and registered a low of $61,581 during Q1 2022.
  • Over the past 3 years, Axsome Therapeutics' median Gains from Sales and Divestitures value was $226,323 (recorded in 2024), while the average stood at $222,922.
  • Data for Axsome Therapeutics' Gains from Sales and Divestitures shows a peak YoY soared of 161.15% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $81,639 in 2022, then skyrocketed by 138.15% to $194,425 in 2023, then surged by 37.73% to $267,779 in 2024, then increased by 19.48% to $295,835 in 2025.
  • Its Gains from Sales and Divestitures was $295,835 in Q3 2025, compared to $268,394 in Q2 2025 and $244,299 in Q1 2025.